Results 1 to 10 of about 5,674 (178)

Repurposing daclatasvir for MASLD Therapy—A promising step forward with challenges ahead [PDF]

Journal of Lipid Research
The article discusses the potential of repurposing daclatasvir, an FDA-approved anti-HCV drug, for treating metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH ...
Carlos Jose Pirola
doaj   +3 more sources

Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2 [PDF]

Journal of Lipid Research
Metabolic dysfunction-associated steatohepatitis (MASH) has become a global health challenge with limited therapeutic strategy. Here, this study aims to identify promising drug candidates for MASH and clarify its pharmacological mechanism.
Rui Shu, Song Tian, Weiyi Qu, Jinjie Yang, Wei Shi, Xinyan Li, Toujun Zou, Changjin Jiang, Yuxuan Zhang, Zifeng Yang, Han Tian, Hailong Yang, Jiajun Fu, Zhi-Gang She, Hongliang Li, Xiao-Jing Zhang   +15 more
doaj   +2 more sources

The Effectiveness of a Sofosbuvir/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis [PDF]

Medicina
Background and Objectives: Hepatitis C virus (HCV) infection is highly prevalent among patients undergoing chronic hemodialysis in emerging countries and is associated with significant morbidity and mortality in this population.
Sidi Mohamed Mah, Soufiane Sid’Ahmed, Mohamed Lemrabott, Delahi Welli, Jemal Awa, Abdellatif Sidi Aly, Lionel Rostaing   +6 more
doaj   +2 more sources

Efficacy and safety of sofosbuvir plus daclatasvir in hemodialysis patients with genotype 1b or 2a hepatitis C virus infection: a single-arm, prospective real-world study [PDF]

Frontiers in Medicine
Background/aimsThis investigation assessed the clinical outcomes and adverse effects of combination therapy using sofosbuvir (SOF) and daclatasvir (DCV) among dialysis-dependent patients infected with hepatitis C virus (HCV) genotypes 1b or 2a in real ...
Kaili Wang, Hongyu Yao, Xia Zhou, Hongling Liu, Jun Zhao   +4 more
doaj   +2 more sources

EVALUATION OF THE SAFETY AND RESISTANCE ASSOCIATED VARIANTS OF SOFOSBUVIR/DACLATASVIR AMONG EGYPTIAN PATIENTS WITH HEPATITIS C VIRUS: A PROSPECTIVE STUDY [PDF]

Bulletin of Pharmaceutical Sciences. Assiut University, 2022
Background: Hepatitis C virus (HCV) is a major health problem. Current treatment by direct-acting antivirals achieved high sustained virological response (SVR). However, drug intolerance or relapse may occur.
, Soha Abdel-Monem, Hala Ahmed, Helal Hetta, Haidi -Allah Ramadan, Ahlam Ahmed, Rasha Omar   +5 more
doaj   +1 more source

The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations

Archives of Pharmaceutical Sciences Ain Shams University, 2022
Renal Organic Cation Transporter 2 (OCT2) plays a major role in metformin elimination. Daclatasvir, a Direct-Acting Antiviral (DAA), is an OCT2 inhibitor.
Mohamed Raslan, Lamia Elwakeel, Sara Shahin   +2 more
doaj   +1 more source

Comparative study of four innovative earth-friendly platforms for rapid analysis of daclatasvir dihydrochloride: Application on different matrices

BMC Chemistry, 2023
Background Daclatasvir dihydrochloride has important roles not only in the management of COVID-19 pandemic symptoms but also in the treatment of chronic hepatitis C infection.
Rania A. Sayed, Ahmed R. Mohamed, Wafaa S. Hassan, Manal S. Elmasry   +3 more
doaj   +1 more source

Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX – REVOLUTIOn trialResearch in context

The Lancet Regional Health. Americas, 2023
Summary: Background: Repurposed drugs for treatment of new onset disease may be an effective therapeutic shortcut. We aimed to evaluate the efficacy of repurposed antivirals compared to placebo in lowering SARS-CoV2 viral load of COVID-19 patients ...
Israel S. Maia, Aline Marcadenti, Viviane C. Veiga, Tamiris A. Miranda, Samara P.C. Gomes, Mariana B.S. Carollo, Karina L. Negrelli, Jackeline O. Gomes, Lucas Tramujas, Erlon O. Abreu-Silva, Glauco A. Westphal, Ruthy P. Fernandes, Jacques G.A. Horta, Deborah C. Oliveira, Uri A.P. Flato, Ricardo C.R. Paoliello, Camilo Fernandes, Cássio L. Zandonai, Juliana C. Coelho, Waldemar C. Barros, Juliana C. Lemos, Renata S. Bolan, Marcela M. Dutra, Otavio C.E. Gebara, Ana T.A. Lopes, Meton S. Alencar Filho, Jussara A. Arraes, Victor A. Hamamoto, Mauro E. Hernandes, Nicole A. Golin, Tiago M. Santos, Renato H.N. Santos, Lucas P. Damiani, Fernando G. Zampieri, João Gesto, Flávia R. Machado, Régis G. Rosa, Luciano C.P. Azevedo, Alvaro Avezum, Renato D. Lopes, Thiago M.L. Souza, Otávio Berwanger, Alexandre B. Cavalcanti   +42 more
doaj   +1 more source

Sofosbuvir and daclatasvir [PDF]

British Journal of Clinical Pharmacology, 2016
Chronic hepatitis C infection is a major cause of chronic liver disease, cirrhosis and liver cancer as well as an important indication for liver transplantation. Sofosbuvir (Sovaldi®) 1 and daclatasvir (Daklinza®) 2 are new direct acting antivirals (DAAs) with a favourable safety and tolerability profile, which have significantly changed treatment for ...
Marleen H. M. Hessel, Adam F. Cohen, Robert Rissmann   +2 more
openaire   +2 more sources

Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients

Journal of Infection in Developing Countries, 2021
Introduction: The conventional interferon therapy of hepatitis C virus has been substituted substantially with sofosbuvir and daclatasvir due to constraints in efficacy and tolerability.
Sonia Younas, Hamid Mukhtar, Umar Farooq Gohar, Abdullah Alsrhani, Badr Alzahrani, Kashaf Junaid, Muhammad Usman Qamar, Hasan Ejaz   +7 more
doaj   +1 more source